Tesofensine

A triple monoamine reuptake inhibitor, not a peptide, tested in phase II obesity trials with reported weight loss.

What research shows

Tesofensine has randomized human trials showing weight loss, having started as a candidate for neurodegenerative disease. It is a triple monoamine reuptake inhibitor rather than a peptide, and despite phase II results it holds no marketing authorisation in the markets we checked.

Evidence strength

Highest evidence grade among the graded claims: B. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.